Bevan Goldswain/E+ via Getty Images Immunocore (NASDAQ:IMCR) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of cancer. It has already received FDA approval of Kimmtrak for the treatment of patients with advanced or metastatic uveal melanoma who are HLAA*02:01-positive. Sales for this drug franchise continue to climb, especially when you consider the reported number. It was stated that in Q2 of 2024, sales of Ki ...

First registrational Phase 3 trial investigating PRAME-targeted therapy "We are very proud to have started the registrational program for brenetafusp, our PRAME candidate, supported by the recent promising brenetafusp monotherapy data in late-line cutaneous melanoma" said Mohammed Dar, Senior Vice President, Clinical Development, and Chief Medical Officer, Immunocore. "The PRISM-MEL301 trial – the first Phase 3 trial for any PRAME-targeted therapy – will test whether combining brenetafusp with nivolumab may ...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafusp (IMC-F106C) in advanced cutaneous melanoma "In both Phase 2 and Phase 3 KIMMTRAK trials, patients with stable disease and durable tumor reduction, regardless of depth, had similar benefit as patients with RECI ...

Core Insights - Immunocore has reported updated Phase 1 data for brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, showing promising clinical activity in late-line cutaneous melanoma patients previously treated with immune checkpoint inhibitors [1][2][3] Phase 1 Clinical Data - Monotherapy with brenetafusp demonstrated a disease control rate (DCR) of 56%, with 4 patients achieving partial response (ORR 11%) and 16 patients showing stable disease [6] - The median progression-free survival (mPFS) for all patients was 4.2 months, with a notable difference in mPFS between PRAME positive (4.2 months) and PRAME negative patients (2.1 months) [7] - Among ctDNA-evaluable PRAME positive patients, 42% exhibited a molecular response, while no PRAME negative patients showed ctDNA reduction [7] Patient Population and Treatment Tolerance - A total of 47 patients received brenetafusp monotherapy, all of whom had prior exposure to immune checkpoint inhibitors, with 100% having received anti-PD1 and 81% anti-CTLA4 [4] - Brenetafusp was well tolerated, with manageable treatment-related adverse events (TRAEs) primarily consisting of Grade 1 or 2 cytokine release syndrome (CRS) and rash [5][8] Combination Therapy Insights - In a cohort of 9 patients receiving brenetafusp in combination with anti-PD1 (pembrolizumab), 4 achieved disease control, including 1 ongoing partial response [9] - The combination therapy was also well tolerated, with manageable TRAEs consistent with the mechanisms of both agents [8] Gene Expression and T Cell Fitness - A gene signature indicating systemic T cell fitness was identified, with patients above the median expression level showing a median PFS of 6 months and a DCR of 69% compared to 2 months and 42% for those below the median [10] Upcoming Trials and Presentations - Immunocore is currently enrolling patients in a Phase 3 clinical trial (PRISM-MEL-301) for brenetafusp combined with nivolumab in first-line advanced cutaneous melanoma, with the primary endpoint being progression-free survival [12][17] - The advanced cutaneous melanoma data from the ongoing Phase 1/2 trial will be presented at the 2024 ASCO Annual Meeting [11]

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...

Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not Applicable | | --- | --- | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 92 Park Drive Milton Park | | | Abingdon, Oxfordshire, United Kingdom | OX14 4RY | | (Address of principal executive offices) | (Zip Code) | | +44 1235 4386 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ________ to ________ Commission File Number 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State o ...

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements | | | Three Months Ended | | Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | | 2023 | 2022 | 2023 | 2022 | | | Notes | £'000 | £'000 | £'000 | £'000 | | Product revenue, net | 3 | 49,719 | 33,252 | 137,285 | 64,926 | | Pre-product revenue, net | 3 | — | 3,05 ...